Thermo Fisher Scientific Reports 5% Revenue Growth to $11.1 Billion in Q3 2025

Thermo Fisher Scientific Inc. reported its financial results for the third quarter of 2025, revealing a total revenue of $11.1 billion, a 5% increase from $10.6 billion in the same period last year. For the first nine months of 2025, revenues reached $32.3 billion, up 3% from $31.5 billion in 2024. The company's net income for the quarter was $1.6 billion, slightly down from $1.6 billion in the prior year, while year-to-date net income increased to $4.7 billion from $4.5 billion. Diluted earnings per share for the quarter were $4.27, compared to $4.25 in the previous year, and $12.53 for the nine months, up from $11.75.

The company experienced notable changes in its operational metrics, with product revenues increasing to $6.5 billion for the quarter, up from $6.1 billion, and service revenues rising to $4.6 billion from $4.5 billion. The increase in revenues was attributed to strong demand in the pharma and biotech markets, although there was a decline in the academic and government sectors due to customer hesitancy amid economic uncertainties. The company also reported a significant increase in inventories, which rose to $5.7 billion from $5.0 billion, reflecting ongoing investments in production capabilities.

Strategically, Thermo Fisher completed the acquisition of Solventum Corporation’s Purification and Filtration business on September 1, 2025, for approximately $3.9 billion. This acquisition is expected to enhance the company's filtration and separation offerings, particularly in the bioproduction sector. Additionally, the company has announced plans to acquire Clario Holdings, Inc. for approximately $8.9 billion, which is anticipated to close in mid-2026, further expanding its capabilities in endpoint data solutions for clinical trials.

In terms of operational performance, the company reported a total employee headcount of approximately 100,000 as of September 27, 2025, reflecting a slight increase from the previous year. The company also noted a strong performance in North America, Europe, and Asia-Pacific, despite challenges in the Chinese market. The Laboratory Products and Biopharma Services and Life Sciences Solutions segments were the primary contributors to organic revenue growth, which was reported at 3% for the quarter and 2% for the year-to-date period.

Looking ahead, Thermo Fisher anticipates continued growth driven by its strategic investments in innovation and expansion of its commercial capabilities. The company expects to maintain its focus on high-impact innovation and enhancing customer partnerships, while also navigating the challenges posed by global economic conditions. The outlook remains positive, with management projecting that the company will continue to generate strong cash flows and maintain a robust financial position.